DrugPatentWatch Database Preview

Details for Patent: 7,572,935

Which drugs does patent 7,572,935 protect, and when does it expire?

Patent 7,572,935 protects APLENZIN and is included in one NDA.

This patent has fifty-one patent family members in seventeen countries.

Summary for Patent: 7,572,935

Title:	Modified release formulations of a bupropion salt
Abstract:	The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s):	Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Turchetta; Stefano (Rome, IT), Massardo; Pietro (Rome, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee:	Biovail Laboratories International S.R.L. (St. Michael, BB)
Application Number:	11/762,840
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,572,935

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-001	Apr 23, 2008		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-002	Apr 23, 2008		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-003	Apr 23, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,572,935

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,645,901	Modified release formulations of a bupropion salt	➤ Sign Up
7,585,897	Modified release formulations of a bupropion salt	➤ Sign Up
7,563,823	Modified release formulations of a bupropion salt	➤ Sign Up
8,932,628	Modified release formulations of a bupropion salt	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 7,572,935

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006261788	➤ Sign Up
Australia	2008285660	➤ Sign Up
Australia	2008320915	➤ Sign Up
Canada	2578626	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,572,935

For more information try a trial or see the plans and pricing